SCHEMBL6508340

SCHEMBL6508340

CCCOCCc1c2c(=O)[nH]c3ccc(Cl)cc3c2nn1C1CCCCO1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDH1 O75874 1/20 0.39
CHEK1 O14757 1/20 0.38
ALDH1A1 P00352 8/20 0.37
KDM4E B2RXH2 7/20 0.37
LMNA P02545 4/20 0.37
MAPK1 P28482 3/20 0.37
HSD17B10 Q99714 3/20 0.37
MAPT P10636 3/20 0.37
HTT P42858 2/20 0.37
TP53 P04637 2/20 0.37
ALOX15 P16050 2/20 0.37
CSF1R P07333 1/20 0.35
HPGD P15428 1/20 0.35
P2RX3 P56373 1/20 0.35
ADORA3 P0DMS8 1/20 0.34
MEN1 O00255 3/20 0.33
KMT2A Q03164 3/20 0.33
POLB P06746 3/20 0.33
RAD51 Q06609 2/20 0.33
ADORA1 P30542 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6515300 0.94 CHEK1 (0.39) IDH1CHEK1ALDH1A1KDM4ELMNA
SCHEMBL6508818 0.91 CHEK1 (0.39) IDH1CHEK1ALDH1A1KDM4ELMNA
SCHEMBL6522020 0.89 CHEK1 (0.43) IDH1CHEK1ALDH1A1KDM4ELMNA
SCHEMBL6510874 0.88 ADORA3 (0.38) IDH1CHEK1ALDH1A1KDM4ELMNA
SCHEMBL6510232 0.85 ADORA3 (0.37) IDH1CHEK1ALDH1A1KDM4ELMNA
SCHEMBL6510097 0.83 IDH1 (0.41) IDH1CHEK1ALDH1A1KDM4ELMNA
SCHEMBL6508753 0.82 CHEK1 (0.47) IDH1CHEK1ALDH1A1KDM4ELMNA
SCHEMBL6514717 0.74 PDE2A (0.44) IDH1CHEK1ALDH1A1KDM4ELMNA
SCHEMBL6510843 0.74 CHEK1 (0.47) IDH1CHEK1ALDH1A1LMNATP53
SCHEMBL6513171 0.73 ATR (0.40) CHEK1ADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050245563-A1 Chk-1 inhibitors MILLENNIUM PHARMACEUTICALS, INC. (US) 2005-11-03 US disclosed
WO-2005028474-A2 PYRAZOLOQUINOLINE DERIVATIVES AS CHK-1 INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2005-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245563-A1 Chk-1 inhibitors CHKA, CHKB, CHEK1 IDH1 3267/4885CHEK1 3/4885ALDH1A1 4635/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.